This report analyzes the issues and trends underlying the syndemics of HIV, SUD, and viral hepatitis in West Virginia.
Resources and Tools
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.
This webinar companion guide provides information for the January 2021 Strengthening Systems of Care: Supporting People with HIV and Opioid Use Disorder following Incarceration webinar.
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
This virtual session summary describes key takeaways from the August 2020 Let's Talk about SSPs as Essential Services conversation.